142285-62-9

Upstream product

• 137649-68-4 (4-benzyloxycarbonylamino-2,3-dihydroxy-1-isobutyl-6-methyl-heptyl)-carbamic acid benzyl ester 
• 142285-44-7 {1-[5-(1-benzyloxycarbonylamino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3-methyl-butyl}-carbamic acid benzyl ester 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 142285-61-8 1-[5-(1-amino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3-methyl-butylamine 

Downstream Products

• 222848-18-2 ((S)-1-{(S)-1-[(S)-1-((4R,5R)-5-{(S)-1-[(S)-2-((S)-2-Benzyloxycarbonylamino-propionylamino)-3-methyl-butyrylamino]-3-methyl-butyl}-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-methyl-butylcarbamoyl]-2-methyl-propylcarbamoyl}-ethyl)-carbamic acid benzyl ester 
• 222848-38-6 (1-{1-[1-(5-{1-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-3-methyl-butyrylamino]-3-methyl-butyl}-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-methyl-butylcarbamoyl]-2-methyl-propylcarbamoyl}-2-methyl-propyl)-carbamic acid benzyl ester 
• 222848-24-0 (1-{1-[1-(5-{1-[2-(2-benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-methyl-butyrylamino]-3-methyl-butyl}-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-methyl-butylcarbamoyl]-2-methyl-propylcarbamoyl}-3-methyl-butyl)-carbamic acid benzyl ester 
• 222848-30-8 (1-{1-[1-(5-{1-[2-(2-benzyloxycarbonylamino-3-phenyl-propionylamino)-3-methyl-butyrylamino]-3-methyl-butyl}-2,2-dimethyl-[1,3]dioxolan-4-yl)-3-methyl-butylcarbamoyl]-2-methyl-propylcarbamoyl}-2-phenyl-ethyl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Development of a new type of protease inhibitors, efficacious against FIV and HIV variants

Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.